OCS
Oculis Holding
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- Oculis completes randomization in the registrational PREDICT-1 trial of licaminlimab for TNFR1-mediated dry eye diseaseOct 19, 2026
- The first patient was treated in the PIONEER-1 registrational trial of privosegtor for optic neuritisAug 24, 2026
- Oculis received positive FDA Pre-IND feedback supporting the development strategy for Privosegtor in acute multiple sclerosis relapsesAug 3, 2026
- Oculis reaches agreement with FDA on SPA for optic neuritis registrational trialMay 7, 2026
- Oculis completed the last patient visit in the Phase 3 DIAMOND program for OCS-01 eye drops in diabetic macular edemaApr 20, 2026